Mr. McBrayer joins AxioMed from Xylos Corporation, a biomaterials company, where he served as Chairman and CEO. Prior to joining Xylos, Mr. McBrayer served as President and CEO of Exogen, Inc., a company focused on the non-invasive treatment of musculoskeletal injury and disease, which was acquired by Smith & Nephew, Inc. in 1999. Previously, Mr. McBrayer was President and CEO of Osteotech, Inc., a worldwide leader in tissue technology. In each of these companies he was responsible for a number of private placements and in the later two companies' public offerings. Prior to joining Osteotech, Mr. McBrayer held positions of increasing responsibility for Johnson & Johnson, Inc.
Jim Kuras, AxioMed's Co-founder and Chief Operating Officer stated, "The team is delighted to have Pat join us at this important stage of our development. He has a broad background in orthopedics including devices, biologics, biomaterials and non-invasive bone repair. One of his patents pioneered biologic repair of the spine thus he fits well with our company of inventors and thought leaders."
AxioMed is financed by a consortium of leading venture capital investors. Pete McNerney, Managing Partner at Thomas, McNerney & Partners, stated, "We selected Pat because he complements our strong management team at AxioMed. In addition to his product development and introduction accomplishments, he has experience in raising private funds and has taken two orthopedic companies public. We intend to build a significant spine company with this fine team."
Contact: AxioMed Spine Corporation, Garfield Heights Patrick McBrayer, 216-587-5566 pmcbrayer@axiomed.com
Source: AxioMed Spine Corporation
